Pharmaceutical composition comprising amphiregulin or mRNA thereof, uterine cavity stent and application
By directly supplementing AREG with exogenous bimodal proteins (AREG mRNA or recombinant protein), the EGFR signaling pathway is activated, promoting the proliferation and angiogenesis of endometrial epithelial cells and vascular endothelial cells. This solves the problem of difficult repair of thin endometrium and achieves a highly efficient and low-toxicity endometrial repair effect.
Patent Information
- Application Number
- CN202610130093.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-01-29
- Publication Date
- 2026-04-21
AI Technical Summary
Existing technologies offer limited treatment options for thin endometrium, with poor efficacy. In particular, the lack of endogenous growth factors makes repair difficult, and hormone therapy has side effects and instability, making it difficult to effectively increase endometrial thickness and restore glandular structure.
By using exogenous bimodal proteins (AREG mRNA or recombinant AREG protein) via a lipid nanoparticle delivery system, AREG in damaged tissues is directly replenished, activating the EGFR signaling pathway, promoting endometrial epithelial cell proliferation and vascular endothelial cell angiogenesis, and restoring endometrial thickness and structure.
It significantly increases endometrial thickness, restores glandular structure, and improves endometrial morphology, solving the repair difficulties caused by insufficient endogenous growth factors. It achieves efficient, low-toxicity, and physiologically rhythmic endometrial repair, avoiding the safety risks of traditional gene therapy and the problem of short half-life of protein drugs.
Smart Images

Figure CN121891507A_ABST
Abstract
Description
Technical Field
[0001] This disclosure relates to the biomedical field, and in particular to pharmaceutical compositions, intrauterine stents, and uses of bimodal proteins or their mRNA. Background Technology
[0002] Successful pregnancy requires a sufficiently thick endometrium and a properly developing embryo. Thin endometrium (TE) is diagnosed as an endometrial thickness ≤7 mm on ultrasound, with a normal uterine cavity morphology, and is closely associated with pregnancy failure. The most common causes of thin endometrium are inadequate endometrial repair after curettage and surgical separation of intrauterine adhesions, accompanied by interrupted vascular distribution and sparse glands. Currently, the cellular and molecular mechanisms of thin endometrium remain unclear, and due to its complex pathogenesis, treatment options for thin endometrium are limited and controversial. Therefore, there is an urgent need to elucidate the functions of different cell types, the regulation of cell proliferation, and the characteristics of thin endometrium in order to develop specific and effective therapies. Summary of the Invention
[0003] Embodiments of this disclosure provide the use of a bimodal protein or its mRNA in the preparation of a medicament for treating uterine-related diseases.
[0004] In some embodiments, uterine-related conditions include thin endometrium, intrauterine adhesions, endometrial atrophy, recurrent implantation failure, or endometrial damage following miscarriage.
[0005] In some embodiments, a thin endometrial lining is defined as an endometrial lining with a maximum thickness of ≤7 mm as measured by transvaginal ultrasound and a normal uterine cavity morphology.
[0006] In some embodiments, the mRNA of the bimodal protein is synthesized by in vitro transcription.
[0007] In some embodiments, bimodal protein mRNA-binding lipid nanoparticles are used as a delivery system.
[0008] Another embodiment of this disclosure provides the use of a bimodal protein or its mRNA in the preparation of a medicament for promoting the proliferation of endometrial epithelial cells.
[0009] Another embodiment of this disclosure provides the use of a bimodal protein or its mRNA in the preparation of a medicament for promoting tubular formation of vascular endothelial cells.
[0010] Another embodiment of this disclosure provides a pharmaceutical composition for treating uterine-related diseases, the pharmaceutical composition comprising a bimodalin or its mRNA, uterine-related diseases including thin endometrium, intrauterine adhesions, endometrial atrophy, recurrent implantation failure, or endometrial damage after miscarriage.
[0011] In some embodiments, the pharmaceutical composition further includes hyaluronic acid gel.
[0012] Another embodiment of this disclosure provides a uterine stent, the surface of which is coated with abitropic protein or its mRNA.
[0013] This disclosure breaks through the limitations of traditional hormone therapy, clarifies the key role of AREG in endometrial repair, and uses AREG mRNA or recombinant AREG protein to exogenously supplement the AREG lacking in damaged tissue. It solves the problems of insufficient endometrial growth factors leading to difficult repair and poor hormone therapy effects in diseases such as thin endometrium and intrauterine adhesions in existing technologies. It can significantly increase endometrial thickness, restore glandular structure, reverse endometrial fibrosis, and fundamentally improve the morphology and structure of the endometrium. Attached Figure Description
[0014] Figure 1 The transfection and expression efficiency of mAREG in endometrial epithelial cells according to some embodiments are shown.
[0015] Figures 2a to 2c The effects of mAREG on endometrial epithelial cell proliferation and vascular endothelial cell angiogenesis were demonstrated.
[0016] Figure 3 The proliferation of endometrial epithelial organoids with AREG overexpression according to some embodiments is shown.
[0017] Figures 4a to 4b The diagram shows statistical graphs of endometrial repair after simulated menstrual cycle bleeding in the AREG-CKO group, wild group, and AREG-CKO supplemented AREG group according to some embodiments. Detailed Implementation
[0018] To enable those skilled in the art to better understand the technical solutions of this disclosure, the technical solutions of this disclosure will be described in detail below with reference to the accompanying drawings.
[0019] Exemplary embodiments will be described more fully below with reference to the accompanying drawings; however, these exemplary embodiments may be embodied in different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will enable those skilled in the art to fully understand the scope of this disclosure.
[0020] Where there is no conflict, the various embodiments of this disclosure and the features thereof in the embodiments may be combined with each other.
[0021] As used herein, the term “and / or” includes any and all combinations of one or more related enumerated entries.
[0022] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit this disclosure. As used herein, the singular forms “a” and “the” are also intended to include the plural forms unless the context clearly indicates otherwise. It will also be understood that when the terms “comprising” and / or “made of” are used in this specification, the presence of the stated feature, integral, step, operation, element, and / or component is specified, but the presence or addition of one or more other features, integrals, steps, operations, elements, components, and / or groups thereof is not excluded.
[0023] Unless otherwise specified, all terms used herein (including technical and scientific terms) have the same meaning as commonly understood by one of ordinary skill in the art. It will also be understood that terms such as those defined in commonly used dictionaries should be interpreted as having a meaning consistent with their meaning in the context of the relevant art and this disclosure, and will not be interpreted as having an idealized or overly formal meaning, unless expressly so defined herein.
[0024] In this disclosure, "about" means a value within a range of ±5% of a specific value. For example, "about 500" includes ±5% of 500, that is, from 475 to 525; "about 50" includes ±5% of 50, that is, from 47.5 to 52.5; "about 30" includes ±5% of 30, that is, from 28.5 to 31.5. Unless otherwise stated, percentages or proportions in this disclosure refer to mass percentages or mass ratios.
[0025] Studies have found that thin endometrial lining is accompanied by increased perivascular cell senescence, and cell growth-related signaling pathways are significantly downregulated at TE. Amphiregulin (AREG), a member of the epidermal growth factor (EGF) family, is expressed by various epithelial and mesenchymal cell lines during development and tissue homeostasis. AREG binds to and activates the EGF receptor (EGFR), triggering downstream signaling pathways (such as RAS / RAF / MEK / ERK, PI3K / AKT), thereby regulating cell proliferation, differentiation, survival, and migration. AREG can induce not only mitotic signaling but also cell differentiation, thus mediating tissue repair. Therefore, AREG also plays a role in endometrial regeneration and repair.
[0026] There is currently no unified standard for the clinical treatment of thin endometrium. Clinically, high-dose estrogen therapy is often the primary treatment, sometimes supplemented with other medications, but the treatment effects vary and remain controversial. Some regimens for women with mid-luteal endometrial thickness <6 mm, involving oral estradiol valerate 16 mg / day for 9 days starting on day 3 of the menstrual cycle, have significantly improved endometrial thickness (≥10 mm), and increased embryo transfer rate and clinical pregnancy success rate. However, high-dose estrogen therapy has a response ceiling, significant systemic side effects, may suppress the endocrine axis, and long-term use may affect endometrial receptivity and quality.
[0027] Granulocyte colony-stimulating factor (G-CSF) can regulate ovarian function through autocrine or paracrine pathways, promoting the secretion of estrogen and progesterone, thereby promoting endometrial repair. It may have some efficacy in the clinical treatment of thin endometrium, but further research is needed to confirm this. In some assisted reproductive cycles, on the day of intramuscular injection of human chorionic gonadotropin (hCG) for ovulation induction, if the endometrial thickness is <7 mm and traditional estrogen and other drug treatments are ineffective, intrauterine injection of G-CSF for (5.2±1.9) days can increase the endometrial thickness to (9.3±2.1) mm. Therefore, the difference in endometrial thickness before and after treatment is statistically significant (P<0.001). However, the evidence level for G-CSF treatment is limited, its efficacy is unstable, its mechanism of action is not fully understood, and there is a potential risk of immune interference.
[0028] This disclosure aims to provide a pharmaceutical composition for promoting endometrial repair and regeneration, and its application, particularly for conditions such as thin endometrium, intrauterine adhesions, and oligomenorrhea. This disclosure utilizes an exogenous amphiregulin (AREG) supplementation strategy, specifically in the form of AREG mRNA (delivered via carriers such as lipid nanoparticles) or recombinant AREG protein.
[0029] AREG is a ligand for the epidermal growth factor receptor (EGFR) and activates downstream MAPK / ERK and PI3K / AKT signaling pathways by binding to EGFR. In environments with endometrial damage or impaired repair, endogenous AREG expression is insufficient. By introducing chemically modified AREG mRNA to improve stability and translation efficiency, or by directly injecting bioactive recombinant AREG protein, the proliferation of endometrial epithelial cells and stromal cells, as well as angiogenesis of vascular endothelial cells, can be significantly promoted, thereby accelerating endometrial repair and restoring endometrial thickness and fertility.
[0030] This disclosure is the first to propose using exogenous AREG (Ag-Adjustable Glutamic Acid) as the core active ingredient to prepare drugs for treating thin endometrium and promoting endometrial repair. This disclosure overcomes the limitations of traditional hormone therapy, clarifying the crucial role of AREG in endometrial repair. By employing AREG mRNA or recombinant AREG protein, it exogenously supplements the AREG lacking in damaged tissue, solving the problems of insufficient endogenous growth factors leading to difficult repair and poor hormone therapy efficacy in diseases such as thin endometrium and intrauterine adhesions. It can significantly increase endometrial thickness, restore glandular structure, reverse endometrial fibrosis, and fundamentally improve the morphology and structure of the endometrium. Furthermore, this disclosure achieves highly efficient, low-toxicity, and physiologically rhythm-compliant endometrial repair through the use of an AREG mRNA delivery strategy. AREG mRNA, synthesized using in vitro transcription technology (preferably combined with delivery systems such as lipid nanoparticles), is introduced into endometrial epithelial and stromal cells. By utilizing the non-integrating and transient expression characteristics of mRNA, this method addresses the risks of genome integration and potential safety issues associated with long-term overexpression in traditional gene therapies (such as viral vectors), while also resolving the short half-life problem of protein drugs. This disclosure demonstrates that AREG mRNA transfection efficiency is high, reaching peak protein expression within 24 hours, mimicking the physiological protein burst expression during endometrial repair, effectively promoting cell proliferation, and exhibiting enhanced safety. Furthermore, this disclosure reveals and utilizes the dual synergistic mechanism of AREG in "proliferation promotion" and "angiogenesis promotion." It not only utilizes AREG to promote the proliferation of endometrial epithelial and stromal cells but also specifically leverages its ability to promote vascular endothelial cell tube formation, resolving the problem of poor repair quality and endometrial dysfunction caused by simply promoting epithelial growth while neglecting blood supply reconstruction. By simultaneously reconstructing the tissue structure and microvascular network, the quality of the repaired endometrium is significantly improved, making it closer to its natural physiological state.
[0031] The following description, in conjunction with specific embodiments, will provide a better understanding of this disclosure.
[0032] Example 1: Verification of AREG mRNA's In Vitro Promotion of Endometrial Cell Population Proliferation and Angiogenesis In this embodiment, a highly efficient AREG mRNA was constructed, and its transfection efficiency and growth-promoting function were verified in various endometrial-associated cell lines.
[0033] 1. Preparation and transfection of AREG mRNA 1.1 A DNA template containing a T7 promoter, 5'UTR, AREG coding region (CDS), 3'UTR and Poly(A) tail was constructed, and AREG mRNA was synthesized by in vitro transcription (IVT) and then capped.
[0034] T7 promoter (SEQ ID NO: 1): 5'-TAATACGACTCACTATA-3' 5' UTR (SEQ ID NO: 2): 5'-CTGAAGATAAAATTACAG-3' AREG coding region (CDS) (SEQ ID NO: 3): 5'-ATGAGAACTCCGCTGCTACCGCTGGCGCGCTCAGTGCTGTTGCTGCTGGTCTTAGGCTCAGGCCATTATGCAGCTGCTTTGGAGCTCAATGACCCCAGCTCAGGGAAAGGCGAATCGCTTTCTGGGGACCACAGTGCCGGTGGACTTGAGCTTTCTGTGGGAAGAGAGGTTTCCACCATAAGCGAAATGCCTTCTGGCAGTGAACTCTCCACAGGGGACTACGACTACTCAGAGGAGTATGATAATGAACCACAAATATCCGGCTATATTATAGATGATTCAGTCAGAGTTGAACAGGTGATTAAGCCCAAGAAAAACAAGACAGAAGGAGAAAAGTCTACAGAAAAACCCAAAAGGAAGAAAAAGGGAGGCAAAAATGGAAAAGGCAGAAGGAATAAGAAGAAAAAGAATCCATGCACTGCCAAGTTTCAGAACTTTTGCATTCATGGCGAATGCAGATACATCGAGAACCTGGAGGTGGTGACATGCAATTGTCATCAAGATTACTTTGGTGAACGGTGTGGAGAAAAATCCATGAAGACTCACAGCGAGGATGACAAGGACCTATCCAAGATTGCAGTAGTAGCTGTCACTATCTTTGTCTCTGCCATCATCCTCGCAGCTATTGGCATCGGCATCGTTATCACAGTGCACCTTTGGAAACGATACTTCAGGGAATATGAAGGAGAAACAGAAGAAAGAAGGAGGCTTCGACAAGAAAATGGGACTGTGCACGCCATTGCCACG-3' 3' UTR and Poly(A) tail (SEQ ID NO: 4): 5'-GATATCACATTGGAGTCACTGCCAAGTCATAGCCATAAATGATGAGTCGGTCCTCTTTCCAGTGGATCATAAGACAATGGACCCTTTTTGTTATGATGGTTTTAAACTTTCAATTGTCACTTT TTATGCTATTTCTGTATATAAAGGTGCACGAAGGTAAAAAGTATTTTTTCAAGTTGTAAATAATTTATTTAATATTTAATGGAAGTGTATTTATTTTACAGCTCATTAAACTTTTTTAACCAAA-3' AREG mRNA preparation process: PCR amplification: AREG DNA bands were obtained using the AREG template plasmid. Primers were designed as follows: front primer (SEQ ID NO: 5): GTAATCGACTCACTATAAGGCGGCCGGGAATTCG; back primer (SEQ ID NO: 6): GGGGTCACAGGGATGCCACCC. The 50 μl PCR system (Takara) consisted of: 2 x Taq Master Mix 25 μl, front primer 2 μl, back primer 2 μl, template 1 μl, and ddH2O 20 μl. PCR reaction: 94℃ for 30 s, 55℃ for 30 s, 72℃ for 60 s, for 30 cycles. AREG DNA bands were obtained after agarose gel electrophoresis. DNA was extracted using a purification kit (Beijing TransGen Biotech Co., Ltd.).
[0035] In vitro transcription: mRNA was prepared using an IVT kit (Shanghai Hexincheng Biotechnology). The 30 μl mixture contained: 10 μl Nuclease-free water, 1.5 μl 10x Reaction Buffer, 1.5 μl ATP (100 mM), 1.5 μl GTP (100 mM), 1.5 μl CTP (100 mM), 1.5 μl N1-Ψ (100 mM), 10 μl Template DNA, 0.825 μl Enzyme Mix 1, and 1.5 μl T7 Enzyme Mix 2. The mixture was incubated at 37°C for 2 hours.
[0036] Tailing reaction: 100 μl system (Shanghai Hexincheng Biotechnology): DEPC-treated Water 45.5 μl, 10X PAPReaction Buffer 10 μl, 10 mM ATP 10 μl, RNase Inhibitor (40 U / μl) 2.5 μl, RNA 30 μl, E. coli Poly(A) Polymerase (5 U / μl) 2 μl. Incubate at 37℃ for 60 min. After the reaction, purify RNA by LiCl precipitation: ① Add 45 μl of 8M LiCl to the 100 μl system, bringing the final concentration to 2.5 M; ② Incubate at -20℃ for at least 30 minutes, then centrifuge at 12000 rpm for 15 min; ③ After removing the supernatant, wash the precipitate once with 70% ethanol, then centrifuge at 12000 rpm for 5 min; ④ Dissolve the precipitate in 50 μl of nuclease-free water to obtain AREG mRNA.
[0037] 1.2 Cell Models: Human endometrial epithelial cell line (12Z, Wuhan Pronosai Life Science Co., Ltd.), human primary endometrial stromal cells, and human umbilical vein endothelial cells (HUVEC, Merck Life Sciences Co., Ltd.) were selected.
[0038] 1.3 Transfection Procedure: Culture cells to 70-80% confluence. Mix AREG mRNA (1 μg / well, 12-well plate) with transfection reagent (Lipofectamine MessengerMAX) at the specified ratio (1 μg mRNA to 1.5 μl LipoMAX per well), incubate at room temperature to form a complex, and then add the mixture to the cells. Detection was performed at different time gradients (2h, 6h, 12h, 24h, 48h).
[0039] 2. Verification of transfection efficiency (Western Blot and immunofluorescence) 2.1 Western Blot: Cells were collected at different time points after transfection, and proteins were extracted by RIPA lysis (Beyotime Biotechnology). After separation by SDS-PAGE, transfer to a membrane, and blocking with 5% BSA, the cells were incubated with anti-AREG primary antibody (Proteintech) and HRP secondary antibody for enhanced chemiluminescence (ECL) imaging.
[0040] 2.2 Immunofluorescence (IF): Discard the culture medium, wash twice with PBST, fix with 4% paraformaldehyde (PFA) at room temperature for 15 min, and wash three times with PBST. Permeabilize with 0.1% Triton X-100 at room temperature for 10 min, and block with 5% BSA at room temperature for 1 h. Incubate overnight at 4°C with the corresponding primary antibody (1:100). Wash three times with PBST. Incubate with rabbit secondary antibody (1:500) at room temperature in the dark for 1 h, and wash three times with PBST. Stain with 4',6-diamidinyl-2-phenylindole (DAPI) (1:1000) for 5 min, and wash three times with PBST. Mount with antifluorescence quenching mounting medium and store in the dark. Image acquisition and analysis were performed using a fluorescence microscope.
[0041] 3. Biological Function Verification 3.1 Epithelial cell viability (CCK8): Endometrial epithelial cell line 12Z was seeded in 96-well plates. The control group was transfected with GFP mRNA (APXxBIO) for 24 h, and the experimental group was transfected with AREG mRNA for 2 h, 6 h, 12 h, 24 h, and 48 h. The experiment was terminated at each well. 10 ml of CCK8 solution (10%) (Biosharp) and 100 μl of DMEM F12 medium (C11995500CP, Gibcol) containing 10% FBS were added to each well of the 96-well plate. The plates were incubated at 37°C in a 5% CO2 incubator for 1 h and then analyzed by microplate reader.
[0042] 3.2 Angiogenesis Assay: Nine hours after transfecting AREG mRNA into HUVECs, Matrigel tube formation assays were performed: a. Thaw the Matrigel (Merck Life Sciences, 4°C overnight) in advance, prepare 24-well plates, use yellow pipette tips, and pre-cool in an ice box at -20°C. b. Add PBS (Gibcol) between the wells to prevent the gel from drying out. On ice: Add 20 μl of Matrigel to each well (drop vertically to the center). Gently push the drop with a 200 μl pipette tip or other tool. Place the 24-well plate in a sealed bag and incubate at 4°C overnight. c. Incubate the 24-well plate at 37°C for 30 min. d. Digestion, centrifugation, and resuspending (cells pretreated with drugs for 6-8 hours): Digest with 0.25% trypsin (Gibcol) at 37°C for 5 minutes. Add 1 ml of DMEM F12 medium (C11995500CP, Gibcol) containing 10% FBS to terminate digestion. Centrifuge at 1500 rpm for 5 minutes. Add 1 ml of DMEM F12 medium (C11995500CP, Gibcol) containing 10% FBS and resuspend by pipetting. Count the cells. Add 100,000 cells per well of a 24-well plate in 500 μl.
[0043] like Figures 1 to 2cAs shown, the cell proliferation rate (OD value) of the GFP mRNA group (control group) was significantly lower than that of the AREG mRNA group (P<0.01), and the angiogenesis index (tube length) was lower.
[0044] Example 2: Recombinant AREG protein rescues delayed endometrial repair caused by AREG deficiency This embodiment uses a conditional knockout mouse model to verify the damage to repair caused by endogenous AREG deficiency and to demonstrate the therapeutic effect of exogenous recombinant AREG protein.
[0045] 1. Construction of AREG conditional knockout (cKO) mice Using the Cre-LoxP system, AREG flox / flox female mice were crossed with PR Cre / + male mice to obtain uterine progesterone receptor (PR) specific knockout mice (AREG flox / flox; PR Cre / +, experimental group) and control mice (AREGflox / flox; PR + / +). The knockout efficiency of AREG protein in uterine tissue was confirmed by Western blotting.
[0046] 2. Simulated Menstrual Bleeding and Repair Model 2.1 Establishment of a mouse model simulating menstrual bleeding: The process of endometrial shedding and repair was simulated in ovariectomized mice. The specific procedure was as follows: 20 eight-week-old AREG flox / flox; PR Cre / + female mice were selected as the experimental group, and 20 AREG flox / flox; PR + / + female mice were selected as the control group. On day 1 of the experiment, ovariectomy was performed on the female mice to eliminate endogenous steroid secretion. From day 7 to day 9, β-estradiol dissolved in peanut oil (100 ng) was injected subcutaneously daily. On day 13, a progesterone sustained-release agent was implanted subcutaneously, and estradiol was injected additionally daily from day 13 to day 15 (5 ng). On day 15, after anesthesia, 20 μl of peanut oil was injected into one uterine horn to induce decidualization. On day 4 (day 19) after decidualization, the progesterone sustained-release agent was removed to simulate progesterone withdrawal. Mice were sacrificed by cervical dislocation at 24 hours (T24) and 48 hours (T48) after progesterone withdrawal, respectively. Uterine tissue was collected and preserved in 4% neutral buffered formalin (for paraffin embedding) and liquid nitrogen for quick freezing (for protein extraction), respectively. Ten biological replicates were set up for each time point.
[0047] 2.2 Assessment of Endometrial Repair in Conditional Knockout Mice: 5μm mouse uterine sections were stained with hematoxylin and eosin (H&E). The morphological characteristics of the post-hemorrhagic endometrium were graded as follows: ① Decidualized: Thickened stroma, glandular displacement, forming typical decidual structure. ② Early breakdown: Loose cell connections, but overall structure preserved. ③ Complete breakdown: Complete destruction of the decidual zone, partial separation of the endometrium from the myometrium. ④ Early repair: Epithelial regeneration initiated, clearing necrotic tissue. ⑤ Complete repair: Complete reconstruction of the stroma and epithelium, leaving only minor fragments in the uterine cavity. Independent observers graded the rupture / repair stage of the mouse uterine H&E sections according to this scoring system.
[0048] 3. Salvage therapy of recombinant AREG protein 3.1 Treatment regimen: While progesterone withdrawal induced bleeding, recombinant mouse AREG protein (10 μl, concentration 100 μg / ml) was injected into the uterine cavity of one uterine horn of AREG cKO mice, and an equal amount of PBS was injected into the contralateral side as a self-control.
[0049] 3.2 Result evaluation: Histological analysis was performed 48 hours after treatment.
[0050] like Figure 4a and Figure 4b As shown, the repair level of AREG-CKO mice was significantly delayed compared to the control group 24 h and 48 h after uterine bleeding; while the repair scores of cKO mice treated with recombinant AREG protein were significantly improved. This demonstrates that endogenous AREG is essential for repair, and that exogenous protein supplementation can completely compensate for this deficiency.
[0051] Example 3: Verification of AREG function based on human endometrial epithelial organoid model In this embodiment, AREG was exogenously supplemented in a human endometrial epithelial organoid model to verify its effect on the proliferation of human endometrial epithelium.
[0052] 1 AREG overexpression and intervention design After the organoids were passaged and stabilized, they were divided into groups for experiments: Control group: human normal endometrial organoid culture medium (abs95101, Absin Biosciences); Recombinant AREG group (R&D Systems): different concentrations of recombinant human AREG protein (10, 50, 100 ng / mL) were added to the culture medium; the intervention time was set at 7-10 days, and the growth rate, diameter changes and branching morphology of the organoids were observed regularly.
[0053] 2. Morphological and Quantitative Index Analysis The diameter, number of cavities, and branching of organoids in different groups were observed using optical and confocal microscopy. ImageJ was used to perform blinded quantitative analysis on at least 30 organoids, and the average value was taken as the final indicator.
[0054] like Figure 3 As shown, monitoring the growth dynamics of endometrial epithelial organoids revealed that AREG overexpression significantly promoted organoid growth. Morphological observation and quantitative diameter analysis showed that on days 4 and 8 of culture, the average diameter of organoids in the AREG-overexpressing group was significantly larger than that in the control group, with statistically significant differences (P<0.05). This demonstrates that the vector or irrelevant sequence alone has no therapeutic effect, and AREG is the key active ingredient responsible for the therapeutic effect.
[0055] This disclosure provides a technical solution for promoting endometrial repair and regeneration using AREG mRNA and recombinant proteins. This solution can significantly promote full-thickness endometrial repair, effectively reversing the pathological state of thin endometrium. By exogenously supplementing AREG (mRNA or protein form), it directly addresses the core technical problem of insufficient endogenous AREG expression in endometrial damage or dysplasia. In a thin endometrial model, the AREG treatment group significantly increased endometrial thickness, promoted glandular regeneration, and reduced fibrosis. Compared with hormone therapy alone, this solution can more directly activate repair signaling pathways, showing breakthrough therapeutic effects for hormone-resistant or mechanically damaged thin endometrium. Furthermore, this solution achieves a dual-mechanism synergistic effect: simultaneously promoting cell proliferation and angiogenesis. Utilizing the pleiotropic properties of AREG, this disclosure achieves a comprehensive remodeling of the endometrial microenvironment: promoting cell proliferation: AREG mRNA or protein can significantly promote endometrial epithelial cells (12Z cells), accelerating epithelial coverage; promoting angiogenesis: this disclosure demonstrates that AREG can significantly enhance the tube-forming ability of vascular endothelial cells. Adequate blood supply is fundamental for endometrial repair, a characteristic that gives this disclosure a unique advantage in treating ischemic or severely damaged endometrial diseases. Furthermore, the mRNA delivery method of this disclosure offers advantages such as high efficiency, low toxicity, and controllability. High efficiency: experiments have shown that AREG mRNA can be efficiently translated into functional proteins within 24 hours of transfection, and protein expression accumulates over time. Safety: compared to viral vectors, the mRNA does not integrate into the host genome, posing no carcinogenic risk; moreover, the mRNA has a short half-life in vivo, and its expression is transient, avoiding the proliferative risks that may arise from long-term overexpression of growth factors, thus better meeting the physiological needs of cyclical endometrial repair. In addition, the recombinant protein form of this disclosure has a rapid onset of action and flexible administration methods. The recombinant AREG protein treatment regimen provided by this disclosure can directly supplement active factors, resulting in a rapid onset of action. In a conditional knockout mouse model, a single intrauterine injection of the recombinant protein can rescue the repair delay caused by gene defects. This form is suitable for local administration, with easily controllable dosage, facilitating the development of intrauterine infusion solutions or sustained-release gel formulations. Based on the key role and significant therapeutic effects of AREG in endometrial repair disclosed in this disclosure, this disclosure can be applied to the following areas: preparation of drugs for treating thin endometrium, and the AREG described in this disclosure. mRNA or recombinant protein can be formulated into pharmaceutical compositions for treating thin endometrium caused by repeated intrauterine procedures, infections, or idiopathic factors, increasing endometrial thickness, improving endometrial receptivity, and thus increasing the success rate of assisted reproductive technology (IVF-ET); drugs or medical devices for treating intrauterine adhesions can be formulated, which can be used as adjuvant therapy after intrauterine adhesion lysis. The drug form is as a postoperative intrauterine irrigation solution to promote rapid epithelialization of the wound and prevent re-adhesion; the device combination involves coating AREG recombinant protein or mRNA-LNP onto an intrauterine stent (such as a balloon or IUD) or mixing it with an anti-adhesion bio-adhesive (such as hyaluronic acid gel) to achieve local sustained drug release, performing biological repair while physically blocking the adhesion; drugs for treating recurrent implantation failure can be formulated. For patients with recurrent implantation failure due to poor endometrial receptivity after excluding embryonic factors, this disclosure provides a novel... Treatment strategies include administering AREG before the implantation window to improve the endometrial microenvironment and increase the probability of embryo implantation; preparation of drugs to promote endometrial repair after induced or medical abortion, which can be applied to post-abortion rehabilitation to accelerate endometrial repair, reduce postoperative bleeding time, lower the risk of postoperative amenorrhea or intrauterine adhesions, and protect women's long-term fertility; preparation of drugs to treat oligomenorrhea and endometrial atrophy, targeting endometrial atrophy and oligomenorrhea caused by premature ovarian failure or perimenopause, which can improve clinical symptoms by stimulating the proliferation of endometrial basal cells through exogenous AREG supplementation; application in endometrial organoid culture and regenerative medicine, in vitro culture: recombinant AREG protein can be added as a key growth factor to the culture medium of endometrial organoids to promote organoid growth and long-term maintenance, for drug screening or disease model construction; tissue engineering: AREG... mRNA or protein is combined with biological scaffold materials to construct tissue-engineered endometrial patches for transplantation and repair of severe endometrial damage; combination therapy: this disclosure can be used in combination with existing hormone therapy, antifibrotic drugs, and stem cell therapy to produce synergistic effects through different mechanisms of action, further improving the cure rate of refractory endometrial damage.
[0056] Example embodiments have been disclosed herein, and while specific terminology has been used, it is for illustrative purposes only and should be construed as such, and is not intended to be limiting. In some instances, it will be apparent to those skilled in the art that features, characteristics, and / or elements described in connection with particular embodiments may be used alone, or in combination with features, characteristics, and / or elements described in connection with other embodiments, unless otherwise expressly indicated. Therefore, those skilled in the art will understand that various changes in form and detail may be made without departing from the scope of this disclosure as set forth by the appended claims.
Claims
1. Use of a bimodal protein or its mRNA in the preparation of a medicament for the treatment of uterine-related diseases.
2. The use according to claim 1, characterized in that, The uterine-related conditions include thin endometrium, intrauterine adhesions, endometrial atrophy, recurrent implantation failure, or endometrial damage after miscarriage.
3. The use according to claim 2, characterized in that, The thin endometrial lining is defined as having a maximum thickness of ≤7 mm as measured by transvaginal ultrasound and a normal uterine cavity morphology.
4. The use according to claim 1, characterized in that, The mRNA of the bimodal protein is synthesized via in vitro transcription.
5. The use according to claim 4, characterized in that, The bimodal protein's mRNA binds to lipid nanoparticles as a delivery system.
6. Use of a bimodal protein or its mRNA in the preparation of a medicament for promoting the proliferation of endometrial epithelial cells.
7. Use of a bimodal protein or its mRNA in the preparation of a medicament for promoting tubular formation of vascular endothelial cells.
8. A pharmaceutical composition for treating uterine-related diseases, characterized in that, The pharmaceutical composition includes a bimodal protein or its mRNA, and the uterine-related diseases include thin endometrium, intrauterine adhesions, endometrial atrophy, recurrent implantation failure, or endometrial damage after miscarriage.
9. The pharmaceutical composition according to claim 8, characterized in that, The pharmaceutical composition also includes hyaluronic acid gel.
10. A uterine stent, characterized in that, The surface of the intrauterine stent is coated with bimodal protein or its mRNA.
